Bilateral recession vs unilateral recession‐resection
Adverse effects (severe, minor) at 6 months · children with infantile esotropia
1 finding from 1 review
- no estimate extracted1 study · 118 participantsVery low
Findings
What do systematic reviews say?
4,756 questions · 11,779 findings · 747 reviews · Headline outcomes only
No studies found 3,205 · 27.2%GRADE not reported 628 · 5.3%Very low 3,261 · 27.7%Low 2,913 · 24.7%Moderate 1,453 · 12.3%High 319 · 2.7%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Prednisone vs placebo or supportive treatment
Persistent kidney disease at any time after treatment · patients with IgAV
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 0.74 [0.42, 1.32]5 studies · 746 participantsModerate
Prednisone vs placebo or supportive treatment
Any continuing kidney disease at 3 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
2 findings from 1 review
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 0.83 [0.46, 1.52]4 studies · 655 participantsModerate
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 0.98 [0.7, 1.36]3 studies · 487 participantsHigh
Prednisone vs placebo or supportive treatment
Children with any continuing kidney disease at 6 months · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 0.51 [0.24, 1.11]3 studies · 379 participantsModerate
Prednisone vs placebo or supportive treatment
Any continuing kidney disease at 12 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
2 findings from 1 review
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 1.06 [0.38, 2.91]3 studies · 455 participantsLow
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 1.39 [0.75, 2.59]2 studies · 287 participantsModerate
Prednisone vs placebo or supportive treatment
Number developing severe kidney disease · patients with IgAV
Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).
1 finding from 1 review
- Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes onlyRR 1.58 [0.42, 6]2 studies · 418 participantsLow
Systemic aminocaproic acid vs placebo
Short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment · people with traumatic hyphema
Systemic aminocaproic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with placebo (low certainty).
1 finding from 1 review
- RR 0.87 [0.57, 1.32]1 study · 34 participantsLow
Topical aminocaproic acid vs placebo
Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Topical aminocaproic acid vs placebo
Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Topical aminocaproic acid vs placebo
Time to resolution of primary hemorrhage · people with traumatic hyphema
1 finding from 1 review
- no estimate extracted2 studies · 142 participantsLow
Topical aminocaproic acid vs placebo
Secondary hemorrhage at any time point · people with traumatic hyphema
Topical aminocaproic acid showed no clear difference in secondary hemorrhage at any time point compared with placebo (low certainty).
1 finding from 1 review
- RR 0.48 [0.2, 1.1]2 studies · 131 participantsLow
Topical aminocaproic acid vs placebo
Adverse effects: systemic hypotension · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Systemic tranexamic acid vs control
Short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment · people with traumatic hyphema
Systemic tranexamic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with control (moderate certainty).
1 finding from 1 review
- RR 1.12 [1, 1.25]4 studies · 425 participantsModerate
Systemic tranexamic acid vs control
Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Systemic tranexamic acid vs control
Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Systemic tranexamic acid vs control
Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Systemic tranexamic acid vs control
Time to resolution of primary hemorrhage · people with traumatic hyphema
1 finding from 1 review
- no estimate extracted5 studies · 549 participantsVery low
Systemic aminocaproic acid vs placebo
Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Systemic tranexamic acid vs control
Secondary hemorrhage at any time point · people with traumatic hyphema
Systemic tranexamic acid may leads to lower secondary hemorrhage at any time point compared with control (low certainty).
1 finding from 1 review
- RR 0.33 [0.21, 0.53]7 studies · 754 participantsLow
Systemic tranexamic acid vs control
Nausea · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found